# Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

> **NCT03427151** · PHASE3 · COMPLETED · sponsor: **ImmuPharma** · enrollment: 62 (actual)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** IPP-201101

## Key facts

- **NCT ID:** NCT03427151
- **Lead sponsor:** ImmuPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-27
- **Primary completion:** 2019-02-05
- **Final completion:** 2019-02-05
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2019-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03427151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03427151, "Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03427151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*